BI India
PharmEasy’s consolidated revenue closed ₹2360 crore in the financial year 2021, which is nearly three times higher than the previous fiscal years. Its net loss has also nearly doubled to ₹641 crore.
Most of the company’s spending was targeted towards purchase of stock-in-trade, which would increase medicine and medical products PharmEasy sells on its platform. The company spent ₹2,266 crore in this regard, compared to ₹699 crore spent last year.
Another ₹270 crore was spent on employee benefits, which includes salaries and wages, gratuity and more. The company’s other expenses — rent, marketing expenses, legal fee and more — also almost doubled ₹481 crore.
It reported a loss of ₹314 crore in the April-June quarter of 2021, as its revenue reached ₹1207 crore.